ArticleWorld journal of gastroenterology2010
Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor.
Article in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 69 citations in OpenAlex.
- Microwave ablation as a primary versus secondary treatment for hepatocellular carcinomaDiagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- Rim Enhancement after Technically Successful Transarterial Chemoembolization in Hepatocellular Carcinoma: A Potential Mimic of Incomplete Embolization or Reactive Hyperemia?Tomography (Ann Arbor, Mich.) · 2022Article
- Clinical and prognostic value of CT perfusion imaging parameters in patients with primary liver cancer after therapy.American journal of translational research · 2022Article
- Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: Impact of Embolic Density and Residual Tumor Perfusion on Tumor Recurrence and Survival.Cardiovascular and interventional radiology · 2021Article
- Applying arterial enhancement fraction (AEF) texture features to predict the tumor response in hepatocellular carcinoma (HCC) treated with Transarterial chemoembolization (TACE).Cancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
- Early Assessment of Response to Radiofrequency Ablation With CT Perfusion Imaging in Rabbit VX2 Liver Tumor Model.Frontiers in oncology · 2021Article
- C-arm cone-beam CT parenchymal blood volume imaging for transarterial chemoembolization of hepatocellular carcinoma: implications for treatment planning and response.European radiology experimental · 2019Article
- Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization.Journal of clinical and translational hepatology · 2018Review
- Computed Tomography Perfusion Imaging for the Diagnosis of Hepatic Alveolar Echinococcosis.The Eurasian journal of medicine · 2018Article
- Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy.Gastroenterology research and practice · 2018Article
- C-arm computed tomography and volume perfusion computed tomography (VPCT)-based assessment of blood volume changes in hepatocellular carcinoma in prediction of midterm tumor response to transarterial chemoembolization: a single center retrospective trial.Cancer imaging : the official publication of the International Cancer Imaging Society · 2016Article
- Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma.World journal of gastroenterology · 2016Review
- The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma.Journal of clinical medicine research · 2016Review
- C-arm computed tomography parenchymal blood volume measurement in evaluation of hepatocellular carcinoma before transarterial chemoembolization with drug eluting beads.Cancer imaging : the official publication of the International Cancer Imaging Society · 2015Article
- Imaging of HCC-Current State of the Art.Diagnostics (Basel, Switzerland) · 2015Review
- Review
- Role of Perfusion CT Differentiating Hemangiomas from Malignant Hepatic Lesions.Journal of clinical imaging science · 2014Article
- Assessment of blood flow in hepatocellular carcinoma: correlations of computed tomography perfusion imaging and circulating angiogenic factors.International journal of molecular sciences · 2013Article
- Computed Tomography (CT) Perfusion in Abdominal Cancer: Technical Aspects.Diagnostics (Basel, Switzerland) · 2013Article
- New paradigm for management of hepatocellular carcinoma by imaging.Liver cancer · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo asses the value of computed tomography (CT)-perfusion in the detection of residual hepatocellular carcinoma (HCC) vascularization after transarterial chemoembolization (TACE).
methodsThirty-two consecutive patients were prospectively included in this study. All patients had liver cirrhosis and a confirmed HCC lesion which was treated with TACE. One month after treatment, perfusion measurements of treated lesions were carried out. The CT-perfusion (CT-p) protocol was performed with 16 slice multidetector computed tomography which included the following parameters: 8 dynamic slices/scan per 40 scans after iv injection of 50 mL of iodinated contrast (350 mg/mL) at a flow rate of 6 mL/s. Treated lesions were evaluated using dedicated perfusion software, which generated a quantitative colour map of perfusion. The following parameters were considered: hepatic perfusion (HP), arterial perfusion (AP), blood volume (BV), hepatic perfusion index (HPI), and time to peak (TTP). Perfusion parameters were described with quartile values of their distribution and statistically analyzed.
resultsPerfusion parameters of the treated lesions could be quantitatively assessed using CT-p analysis. The presence of residual tumor tissue was observed in 13 of the 32 patients. The values of the perfusion parameters measured within the relapse tissue were: HP (mL/100 g per minute): median = 44.4 (1(st)qt = 31.3, 3(rd)qt = 55.8); BV (mL/100 g): median = 18.7 (1(st)qt = 11.5, 3(rd)qt = 22.5); AP (mL/min): median = 39.0 (1(st)qt = 36.5, 3(rd)qt = 61.3); HPI (%): median = 34.0 (1(st)qt = 30.4, 3(rd)qt = 38.9); TTP (s): median = 17.3 (1(st)qt = 15.8, 3(rd)qt = 26.5). With the use of the univariate paired Wilcoxon signed rank test, HP, AP and HPI were shown to be significantly higher (P < 0.001) in the relapse site than in the primary lesion. The BV and TTP parameters showed a tendency to be greater and lower, respectively, in the relapse site than in the primary lesion.
conclusionIn patients with HCC treated with TACE, CT-p provides measurement of flow parameters related to residual arterial structures in viable tumor, thus helping in the assessment of therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.